【摘 要】
：
Background and Aims: The survival rate of patients with hepatocellular carcinoma is variable. The abnormal expres-sion of RNA-binding proteins (RBPs) is closely related to the occurrence and development of malignant tumors. The pri-mary aim of this study
【机 构】
：
Department of Hepatobiliary and Pancreatic Surgery,Zhongnan Hospital of Wuhan University,Wuhan,Hubei
论文部分内容阅读
Background and Aims: The survival rate of patients with hepatocellular carcinoma is variable. The abnormal expres-sion of RNA-binding proteins (RBPs) is closely related to the occurrence and development of malignant tumors. The pri-mary aim of this study was to identify RBPs related to the prognosis of liver cancer and to construct a prognostic model of liver cancer. Methods: We downloaded the hepatocellular carcinoma gene sequencing data from The Cancer Genome Atlas (cancergenome.nih.gov/) database, constructed a pro-tein-protein interaction network, and used Cytoscape to real-ize the visualization. From among 325 abnormally expressed genes for RBPs, 9 (XPO5, enhancer of zeste 2 polycomb re-pressive complex 2 subunit [EZH2], CSTF2, BRCA1, RRP12, MRPL54, EIF2AK4, PPARGC1A, and SEPSECS) were selected for construction of the prognostic model. Then, we further verified the results through the Gene Expression Omnibus (www.ncbi.nlm.nih.gov/geo/) database and in vitro experi-ments. Results: A prognostic model was constructed, which determined that the survival time of patients in the high-risk group was significantly shorter than that of the low-risk group (p<0.01). Univariate and multivariate Cox regression analysis suggested that the risk score was an independent prognostic factor (p<0.01). We also constructed a nomogram based on the risk score, survival time, and survival status. At the same time, we verified the high expression and cancer-promoting effects of EZH2 in tumors. Conclusions: Survival, receiver operating characteristic curve and independent prognostic analyses demonstrated that we constructed a good prognos-tic model, which might be useful for estimating the survival of patients with hepatocellular carcinoma.
其他文献
A panel of experts from 22 countries recently proposed a name change from nonalcoholic fatty liver disease (NAFLD) to metabolic-associated fatty liver disease, or MAFLD.1 Sub-sequently, new criteria for diagnosing MAFLD were provided to help guide clinici
To the editor,rnThere remains a huge unmet need for treatment of cir-rhotic ascites. In this letter, we propose that the sodium-glucose cotransporter-2 (SGLT2) inhibitor may be a promis-ing complement for current therapy.
Background and Aims: The immune system plays vital roles in hepatocellular carcinoma (HCC) initiation and pro-gression. The present study aimed to construct an immune-gene related prognostic signature (IRPS) for predicting the prognosis of HCC patients. M
Spontaneous bacterial peritonitis (SBP) is defined as infec-tion in ascites fluid without evidence of an intra-abdominal treatable source.1 Diagnosis is confirmed by presence of ≥250 cells/mm3 polymorphonuclear cells (PMNs).2 Although SBP responds well to
Background and Aims: Primary biliary cholangitis (PBC) is a chronic liver disease that negatively affects the health-related quality of life (HRQoL) of patients. Furthermore, the HRQoL of Chinese patients has been neglected for a long time. The present st
Background and Aims: Timely and effective assessment scoring systems for predicting the mortality of patients with hepatitis E virus-related acute liver failure (HEV-ALF) are urgently needed. The present study aimed to establish an effective nomogram for
Background and Aims: Intrahepatic cholangiocarcinoma (ICC) is a malignant tumor derived from intrahepatic bile duct epithelial cells. Accumulating studies report that mi-croRNAs are widely involved in tumor migration and me-tastasis by regulation of targe
Background and Aims: This study aimed to determine the performance of the non-invasive score using noncontrast-enhanced MRI (CHESS-DIS score) for detecting portal hy-pertension in cirrhosis. Methods: In this international mul-ticenter, diagnostic study (C
Background and Aims: Chronic hepatitis B is the main cause of liver cancer. However, the most neglected group has been treatment-naive chronic hepatitis B patients with normal alanine aminotransferase (ALT). People have tended to subjectively assume that
Background and Aims: In the last decade, several sec-ond-line therapies followed by sorafenib in patients with ad-vanced hepatocellular carcinoma (HCC) have been reported. But the outcomes were different from each other. This me-ta-analysis aimed to evalu